Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.
Stock data | 2024 | Change |
---|---|---|
Price | $0.0002 | N/A |
Market Cap | $0 | N/A |
Shares Outstanding | 0 | N/A |
Employees | 450.00 | N/A |